ArticleBMC urology2025
Prognostic impact of non-clear cell histology on recurrence and cancer-free survival in renal cell carcinoma: a time-to-event analysis.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine risk factors associated with the recurrence of renal cell carcinoma (RCC), either local recurrence or distant metastasis, and to characterize a contemporary cohort of patients with non-clear RCC (ncRCC) in terms of cancer-free survival (CFS) and time to such recurrence.
methodsA retrospective review of prospectively collected data was performed for consecutive patients undergoing partial and radical nephrectomy at a tertiary care center in Saudi Arabia. Data collection included patients and tumor characteristics, perioperative parameters, and histopathological patterns. Multivariate logistic regression determined the predictors of tumor recurrence while Kaplan-Meier analyses assessed CFS and the time to recurrence.
resultsA total of 214 patients were analyzed, including 150 (70.1%) ccRCC and 64 (29.9%) ncRCC, with a mean age of 54.8 ± 1.7 years and tumor size of 6.9 ± 0.7 (1.2-24.0) cm. After a median follow-up of 47.6 ± 12.4 months, 32(14.9%) patients developed recurrence. In multivariate regression, tumor recurrence was significantly associated with tumors ≥ 6.9 cm [aOR (95% CI): 2.85 (1.67-5.43)], renal vein or inferior vena cava vascular invasion [aOR: 1.92 (1.32-4.21)], pathological staging ≥ 2b [aOR: 2.66 (1.95-5.34)] (8th edition of the AJCC Cancer Staging Manual, 2017), and positive lymph nodes in the specimen [aOR: 3.28 (2.97-5.15)]. The recurrence-free status was 85% at 5 years, while the mean time to recurrence was 9 (6-42) months. Patients with ncRCC had comparable recurrence rates to those with ccRCC (12.5% vs. 16.0% p = 0.64), respectively. The 5-year CFS was 62.8% (95% CI: 54.2-68.7) for ncRCC and 76.8% (95% CI: 67.4-87.2) for ccRCC (p = 0.77).
conclusionCompared to clear cell RCC, patients with non-clear cell RCC showed no significant differences in demographic, tumor, or perioperative characteristics. In our cohort, both histopathological subtypes demonstrated comparable recurrence rates and 5-year cancer-free survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.